Corrigendum to 'Supporting clinical decision making in advanced melanoma by preclinical testing in personalized immune-humanized xenograft mouse models': Annals of Oncology Volume 31, Issue 2, Pages 266-273

Affiliations

¹ Sahlgrenska Cancer Center, University of Gothenburg, Gothenburg; Department of Oncology, Institute of Clinical Sciences, University of Gothenburg and Sahlgrenska University Hospital, Gothenburg, Sweden.
² Sahlgrenska Cancer Center, University of Gothenburg, Gothenburg; Department of Surgery, Institute of Clinical Sciences, University of Gothenburg and Sahlgrenska University Hospital, Gothenburg, Sweden.
³ Department of Neurosurgery, Institute of Clinical Sciences, University of Gothenburg and Sahlgrenska University Hospital, Gothenburg, Sweden.
⁴ Sahlgrenska Cancer Center, University of Gothenburg, Gothenburg; Department of Surgery, Institute of Clinical Sciences, University of Gothenburg and Sahlgrenska University Hospital, Gothenburg, Sweden. Electronic address: jonas.a.nilsson@surgery.gu.se.

Free article

Published Erratum

L Ny et al. Ann Oncol. 2020 May.

Free article

. 2020 May;31(5):663.

doi: 10.1016/j.annonc.2020.03.292. Epub 2020 Apr 3.

¹ Sahlgrenska Cancer Center, University of Gothenburg, Gothenburg; Department of Oncology, Institute of Clinical Sciences, University of Gothenburg and Sahlgrenska University Hospital, Gothenburg, Sweden.
² Sahlgrenska Cancer Center, University of Gothenburg, Gothenburg; Department of Surgery, Institute of Clinical Sciences, University of Gothenburg and Sahlgrenska University Hospital, Gothenburg, Sweden.
³ Department of Neurosurgery, Institute of Clinical Sciences, University of Gothenburg and Sahlgrenska University Hospital, Gothenburg, Sweden.
⁴ Sahlgrenska Cancer Center, University of Gothenburg, Gothenburg; Department of Surgery, Institute of Clinical Sciences, University of Gothenburg and Sahlgrenska University Hospital, Gothenburg, Sweden. Electronic address: jonas.a.nilsson@surgery.gu.se.

No abstract available

Erratum for

Supporting clinical decision making in advanced melanoma by preclinical testing in personalized immune-humanized xenograft mouse models.
Ny L, Rizzo LY, Belgrano V, Karlsson J, Jespersen H, Carstam L, Bagge RO, Nilsson LM, Nilsson JA. Ny L, et al. Ann Oncol. 2020 Feb;31(2):266-273. doi: 10.1016/j.annonc.2019.11.002. Epub 2020 Jan 3. Ann Oncol. 2020. PMID: 31959343